Title:
DRUGS FOR INHIBITING REJECTION REACTION IN TISSUE TRANSPLANTED INTO MAMMALIAN TISSUE AND METHOD OF TREATING DIABETES USING THE SAME
Document Type and Number:
WIPO Patent Application WO/2004/054618
Kind Code:
A1
Abstract:
It is intended to provide a drug whereby a rejection reaction in tissue transplantation into a recipient can be regulated and a therapeutic method. To achieve the above objects, this drug, which aims at inhibiting a rejection reaction in a tissue transplanted into a mammal, is characterized by containing an ingredient in a dose efficacious in controlling the effect of natural killer cells in the mammal after the transplantation.
Inventors:
YASUNAMI YOHICHI (JP)
TANIGUCHI MASARU (JP)
TANIGUCHI MASARU (JP)
Application Number:
PCT/JP2003/007986
Publication Date:
July 01, 2004
Filing Date:
June 24, 2003
Export Citation:
Assignee:
JAPAN SCIENCE & TECH CORP (JP)
YASUNAMI YOHICHI (JP)
TANIGUCHI MASARU (JP)
YASUNAMI YOHICHI (JP)
TANIGUCHI MASARU (JP)
International Classes:
A61K39/395; A61K45/00; A61K48/00; A61P3/10; (IPC1-7): A61K45/00; A61K39/395; A61K48/00; A61P3/10
Other References:
JEAN-CLAUDE CAREL et al., "Transforming growth factor beta decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon gamma," Proc. Natl. Sci. USA, Vol. 87, 1990, pages 1591 - 1595
Yasuto IKEHARA ET AL., "CD4+Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice," J. Clin. Invest., Vol. 105, 2000, pages 1761 - 1767
Yasuto IKEHARA ET AL., "CD4+Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice," J. Clin. Invest., Vol. 105, 2000, pages 1761 - 1767
Attorney, Agent or Firm:
Yaguchi, Taro (4th Floor Matrice Bldg. 2-13-7, Minamiaoyam, Minato-ku Tokyo, JP)
Download PDF: